Anti-obesity Prescription Drugs Market by Drug Class (Amylin Analogs, GLP-1 Agonists, Lipase Inhibitors), Administration Route (Injectables, Orals), End User, Distribution Channel - Global Forecast 2025-2032
Description
The Anti-obesity Prescription Drugs Market was valued at USD 6.71 billion in 2024 and is projected to grow to USD 7.25 billion in 2025, with a CAGR of 8.35%, reaching USD 12.77 billion by 2032.
Comprehensive introduction explaining how scientific breakthroughs, delivery innovations, commercial pressures, and care pathways are reshaping anti-obesity prescription drug strategies
The anti-obesity prescription drugs landscape has entered a period of rapid evolution driven by scientific innovation, shifting clinical practices, evolving payer considerations, and intensifying commercial focus. This introduction frames the therapeutic, delivery, and commercial dynamics that are reshaping how clinicians, payers, manufacturers, and distributors approach obesity as a chronic disease. It situates the report’s purpose and clarifies the analytical lenses used to interpret clinical trial progress, regulatory actions, supply chain variables, and competitive activity.
Transitioning from a historically limited pharmacologic toolkit to an era of targeted biologics and combination therapies, healthcare systems are adapting treatment algorithms and care pathways. The content that follows emphasizes how drug classes such as Amylin Analogs exemplified by Pramlintide and GLP-1 Agonists including Dulaglutide, Exenatide, Liraglutide, and Semaglutide are influencing clinician prescribing behavior and patient expectations. Concurrently, distinctions in administration routes between injectables-delivered via auto-injectors, prefilled pens, or vials and syringes-and oral formulations in capsules or tablets are shaping adherence, clinic workflows, and device development priorities.
By presenting an integrated view that encompasses distribution channels from offline to online and end users ranging from ambulatory care centers and home care settings to hospitals and specialty clinics such as endocrinology, general practice and weight loss clinics, this introduction sets the stage for a deeper examination of commercial strategies, regional dynamics, regulatory pressures, and actionable priorities for stakeholders operating across the continuum of obesity care.
Transformative shifts driven by therapeutic differentiation, delivery innovations, distribution evolution, and multidisciplinary care integration that redefine commercial and clinical strategies
The landscape has shifted profoundly as next‑generation agents and delivery platforms move from research settings into routine clinical practice. Recent therapeutic advances have elevated GLP-1 Agonists and Amylin Analogs into front-line consideration, while legacy classes such as Lipase Inhibitors represented by Orlistat and Serotonin Receptor Modulators such as Locaserin retain roles for specific patient profiles. As these clinically differentiated options proliferate, healthcare providers are re-evaluating prescribing criteria, follow-up protocols, and combination approaches to maximize patient benefit.
At the same time, the proliferation of injectable formats-auto-injectors, prefilled pens, and vials and syringes-alongside traditional oral formats like capsules and tablets is catalyzing device innovation and operational redesign in clinics and pharmacies. Digital health tools and e-commerce channels are also accelerating patient access, making distribution channel strategy across offline and online pathways a critical consideration for manufacturers and distributors. Furthermore, specialty and generalist care settings from endocrinology clinics to general practice and dedicated weight loss clinics are integrating pharmacotherapy into multidisciplinary care models, thereby expanding the end-user base and driving new training, monitoring, and reimbursement needs.
In sum, transformative shifts encompass therapeutic differentiation, delivery system evolution, expanded distribution modalities, and the emergence of multidisciplinary care pathways, all of which collectively redefine commercialization tactics and patient management frameworks.
Cumulative implications of US tariff changes on supply chains, procurement decisions, clinical logistics, and strategic manufacturing choices across the anti-obesity drug value chain
The imposition of tariffs and trade policy adjustments introduces immediate cost, sourcing, and operational considerations across the value chain for anti-obesity prescription drugs. Tariff changes influence upstream manufacturing decisions, prompting some firms to reassess where active pharmaceutical ingredients and finished products are produced and assembled. This dynamic amplifies the importance of supply chain transparency and dual sourcing strategies to mitigate exposure to tariff-driven cost fluctuations and cross-border logistics constraints.
Clinicians and payers may experience indirect effects as manufacturers respond to tariff pressures by optimizing procurement, adjusting contractual terms with distributors, or altering packaging and device sourcing to control landed costs. Clinical trial logistics and importation of specialized devices or biologic components can also face timing disruptions; consequently, development timelines and regulatory interactions may require recalibration. In response, companies are increasingly evaluating onshore or nearshore manufacturing options, renegotiating supplier agreements, and implementing hedging mechanisms to preserve supply continuity.
Taken together, the cumulative impact of tariffs in 2025 underscores the need for strategic supply chain resilience, adaptive procurement practices, and coordinated policy engagement. Stakeholders that proactively model tariff scenarios, align manufacturing footprints with demand centers, and communicate transparently with payers and providers will be better positioned to sustain program momentum and protect patient access.
Key segmentation insights demonstrating how drug class, administration route, distribution channel, and care setting intersections dictate clinical positioning and commercial execution
Segmentation analysis reveals clinically and commercially meaningful distinctions that influence product strategy, go-to-market planning, and care delivery integration. When analyzed by drug class, the landscape includes Amylin Analogs with Pramlintide; GLP-1 Agonists such as Dulaglutide, Exenatide, Liraglutide, and Semaglutide; Lipase Inhibitors exemplified by Orlistat; and Serotonin Receptor Modulators like Locaserin. These classes differ by mechanism of action, safety profiles, and typical patient selection criteria, thereby guiding clinical positioning and evidence generation priorities.
Administration route segmentation differentiates injectables-delivered via auto-injectors, prefilled pens, or vials and syringes-from orals available as capsules and tablets. Route of administration affects adherence patterns, device partnerships, cold-chain logistics, and patient education needs. Distribution channel segmentation between offline and online pathways further shapes access models, with brick-and-mortar pharmacy and clinic networks interacting differently with digital pharmacies, telehealth prescribing, and direct-to-patient fulfillment. End-user segmentation spans ambulatory care centers, home care settings, hospitals, and specialty clinics; within specialty clinics, distinctions among endocrinology clinics, general practice clinics, and weight loss clinics drive differences in follow-up intensity, diagnostic workup, and ancillary service requirements.
Understanding these intersecting segmentation vectors enables more precise targeting of clinical trials, payer dossiers, and commercial tactics. By aligning product attributes with the operational realities of specific administration routes, distribution channels, and care settings, stakeholders can refine positioning, prioritize evidence generation, and design support services that materially improve uptake and adherence.
Differentiated regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that dictate tailored regulatory, reimbursement, and operational strategies
Regional dynamics create divergent regulatory, reimbursement, and operational conditions that shape how anti-obesity therapeutics are adopted and scaled. In the Americas, regulatory pathways and payer debates around long-term treatment models are driving intensive stakeholder engagement and localized evidence generation to support coverage and access decisions. Clinical practice patterns and consumer expectations in this region also accelerate demand for both specialty clinic adoption and home-based care models.
In Europe, Middle East & Africa, diverse regulatory regimes and heterogeneous reimbursement systems require tailored regulatory strategies and differentiated pricing approaches. Stakeholders must navigate variable clinical guideline uptake and sometimes fragmented distribution networks. Conversely, Asia-Pacific presents rapid adoption of novel therapeutics in some markets, supported by robust manufacturing capabilities and growing digital health ecosystems, while other markets in the region demand culturally sensitive engagement and local evidence to support clinician acceptance. Across all regions, cross-border supply chain considerations, tariff implications, and device compatibility issues underscore the importance of region-specific operational planning.
Taken together, regional insight demands a portfolio approach to regulatory submissions, payer engagement, and commercial deployment, with a focus on local evidence generation, logistics optimization, and adaptive pricing strategies to reflect payer expectations, clinical pathways, and distribution infrastructures.
Company-level strategic imperatives emphasizing collaboration, device integration, real-world evidence, and supply resilience to secure competitive advantage in anti-obesity therapeutics
Competitive dynamics are defined by a mix of established pharmaceutical firms, emerging biotech innovators, and device partners focused on delivery systems. Across therapeutic classes, companies are investing in combination strategies, formulation improvements, and device ergonomics to differentiate offerings and improve patient adherence. Collaboration between biologics developers and device manufacturers is increasingly common, reflecting the need to pair pharmacology with user-friendly administration solutions.
Corporate strategies also reflect a balance between expanding clinical indications and protecting supply continuity. Licensing deals, co-development agreements, and manufacturing partnerships are being used to accelerate access to key components and scale commercial capacity. Regulatory interactions and real-world evidence programs play a central role in shaping competitive advantage, as outcomes data influence payer negotiations and clinician confidence. Additionally, active intellectual property management and lifecycle planning remain critical to preserving therapeutic positioning while pursuing incremental innovations such as new formulations or delivery platforms.
Taken together, company-level insights emphasize execution across clinical development, device integration, supply chain resilience, and payer engagement. Organizations that synchronize these elements with targeted commercialization playbooks and robust evidence generation will gain a sustained edge in an increasingly crowded therapeutic arena.
Actionable recommendations for leaders to align evidence generation, device strategy, supply resilience, payer engagement, and agile commercialization to accelerate adoption
Industry leaders should prioritize an integrated strategy that aligns clinical development, device design, supply chain resilience, and payer engagement. First, invest in targeted evidence generation that demonstrates long-term clinical outcomes, safety across diverse populations, and real-world effectiveness in the settings where the product will be used, including ambulatory, hospital, and home care environments. Second, build robust device and adherence support programs that address route-specific challenges for injectables and oral administration, and pair these with digital health solutions to enable monitoring and patient support.
Third, proactively fortify supply chains by diversifying suppliers, exploring nearshore manufacturing options, and conducting scenario planning for tariff and trade disruptions to maintain continuity of supply. Fourth, engage payers and policy makers early with transparent value models, outcomes-based contracting options, and compelling economic data tailored to regional reimbursement frameworks. Finally, adopt an agile commercialization approach that customizes distribution strategies for offline and online channels and adapts training and support for specialty clinics, endocrinology practices, generalist providers, and weight loss clinics.
Implementing these recommendations requires cross-functional coordination, clear governance, and measurable KPIs to track adoption, adherence, and value realization. Organizations that act on these priorities will be better positioned to accelerate uptake, protect margins, and deliver improved patient outcomes.
Robust hybrid research approach integrating primary interviews, secondary verification, data triangulation, and expert validation to ensure reliable and practical insights
The research methodology underpinning this analysis combines structured primary research with rigorous secondary interrogation and iterative expert validation. Primary research included in-depth interviews with clinical specialists, supply chain managers, regulatory advisors, and commercial leaders to surface practical constraints, adoption drivers, and payer engagement priorities. These interviews informed hypothesis generation and guided targeted follow-ups to validate operational assumptions across therapeutic classes and care settings.
Secondary research drew on peer-reviewed clinical literature, regulatory filings, public policy documents, and device registries to corroborate clinical evidence, safety signals, and approval timelines. Data triangulation techniques integrated qualitative insights with quantitative indicators from clinical trial registries, procurement patterns, and public procurement notices to build a robust evidence base. Finally, findings were stress-tested through expert panels composed of clinicians, payers, and industry executives to confirm plausibility, refine interpretations, and identify practical implications for commercialization and supply chain strategy.
Transparency, reproducibility, and iterative expert feedback were central to the approach, enabling the analysis to capture both near-term operational realities and longer-term strategic implications for therapeutic classes, administration routes, distribution channels, and end-user settings.
Conclusion synthesizing therapeutic, delivery, regional, and operational imperatives that will determine durable clinical and commercial success in obesity therapeutics
The conclusion synthesizes the report’s principal insights: therapeutic innovation, delivery and device evolution, regional and tariff-driven operational shifts, and nuanced segmentation dynamics collectively define the modern anti-obesity prescription drug landscape. As GLP-1 Agonists and Amylin Analogs gain prominence, stakeholders must adapt clinical pathways, invest in adherence-focused device solutions, and tailor payer narratives to demonstrate sustained value in diverse care settings.
Operational resilience will differentiate successful programs, particularly in the face of tariff-induced supply chain pressures that prompt manufacturers and distributors to rethink sourcing and manufacturing footprints. Regional strategies must balance centralized evidence generation with localized implementation tactics responsive to regulatory, reimbursement, and cultural differences. Ultimately, companies that integrate clinical evidence, device usability, distribution agility across offline and online channels, and proactive payer engagement across ambulatory, hospital, home care, and specialty clinic settings will be best positioned to translate therapeutic advances into improved patient outcomes.
In closing, the intersection of science, delivery innovation, and pragmatic commercialization will determine which interventions achieve durable clinical and commercial success in the evolving landscape of obesity therapeutics.
Please Note: PDF & Excel + Online Access - 1 Year
Comprehensive introduction explaining how scientific breakthroughs, delivery innovations, commercial pressures, and care pathways are reshaping anti-obesity prescription drug strategies
The anti-obesity prescription drugs landscape has entered a period of rapid evolution driven by scientific innovation, shifting clinical practices, evolving payer considerations, and intensifying commercial focus. This introduction frames the therapeutic, delivery, and commercial dynamics that are reshaping how clinicians, payers, manufacturers, and distributors approach obesity as a chronic disease. It situates the report’s purpose and clarifies the analytical lenses used to interpret clinical trial progress, regulatory actions, supply chain variables, and competitive activity.
Transitioning from a historically limited pharmacologic toolkit to an era of targeted biologics and combination therapies, healthcare systems are adapting treatment algorithms and care pathways. The content that follows emphasizes how drug classes such as Amylin Analogs exemplified by Pramlintide and GLP-1 Agonists including Dulaglutide, Exenatide, Liraglutide, and Semaglutide are influencing clinician prescribing behavior and patient expectations. Concurrently, distinctions in administration routes between injectables-delivered via auto-injectors, prefilled pens, or vials and syringes-and oral formulations in capsules or tablets are shaping adherence, clinic workflows, and device development priorities.
By presenting an integrated view that encompasses distribution channels from offline to online and end users ranging from ambulatory care centers and home care settings to hospitals and specialty clinics such as endocrinology, general practice and weight loss clinics, this introduction sets the stage for a deeper examination of commercial strategies, regional dynamics, regulatory pressures, and actionable priorities for stakeholders operating across the continuum of obesity care.
Transformative shifts driven by therapeutic differentiation, delivery innovations, distribution evolution, and multidisciplinary care integration that redefine commercial and clinical strategies
The landscape has shifted profoundly as next‑generation agents and delivery platforms move from research settings into routine clinical practice. Recent therapeutic advances have elevated GLP-1 Agonists and Amylin Analogs into front-line consideration, while legacy classes such as Lipase Inhibitors represented by Orlistat and Serotonin Receptor Modulators such as Locaserin retain roles for specific patient profiles. As these clinically differentiated options proliferate, healthcare providers are re-evaluating prescribing criteria, follow-up protocols, and combination approaches to maximize patient benefit.
At the same time, the proliferation of injectable formats-auto-injectors, prefilled pens, and vials and syringes-alongside traditional oral formats like capsules and tablets is catalyzing device innovation and operational redesign in clinics and pharmacies. Digital health tools and e-commerce channels are also accelerating patient access, making distribution channel strategy across offline and online pathways a critical consideration for manufacturers and distributors. Furthermore, specialty and generalist care settings from endocrinology clinics to general practice and dedicated weight loss clinics are integrating pharmacotherapy into multidisciplinary care models, thereby expanding the end-user base and driving new training, monitoring, and reimbursement needs.
In sum, transformative shifts encompass therapeutic differentiation, delivery system evolution, expanded distribution modalities, and the emergence of multidisciplinary care pathways, all of which collectively redefine commercialization tactics and patient management frameworks.
Cumulative implications of US tariff changes on supply chains, procurement decisions, clinical logistics, and strategic manufacturing choices across the anti-obesity drug value chain
The imposition of tariffs and trade policy adjustments introduces immediate cost, sourcing, and operational considerations across the value chain for anti-obesity prescription drugs. Tariff changes influence upstream manufacturing decisions, prompting some firms to reassess where active pharmaceutical ingredients and finished products are produced and assembled. This dynamic amplifies the importance of supply chain transparency and dual sourcing strategies to mitigate exposure to tariff-driven cost fluctuations and cross-border logistics constraints.
Clinicians and payers may experience indirect effects as manufacturers respond to tariff pressures by optimizing procurement, adjusting contractual terms with distributors, or altering packaging and device sourcing to control landed costs. Clinical trial logistics and importation of specialized devices or biologic components can also face timing disruptions; consequently, development timelines and regulatory interactions may require recalibration. In response, companies are increasingly evaluating onshore or nearshore manufacturing options, renegotiating supplier agreements, and implementing hedging mechanisms to preserve supply continuity.
Taken together, the cumulative impact of tariffs in 2025 underscores the need for strategic supply chain resilience, adaptive procurement practices, and coordinated policy engagement. Stakeholders that proactively model tariff scenarios, align manufacturing footprints with demand centers, and communicate transparently with payers and providers will be better positioned to sustain program momentum and protect patient access.
Key segmentation insights demonstrating how drug class, administration route, distribution channel, and care setting intersections dictate clinical positioning and commercial execution
Segmentation analysis reveals clinically and commercially meaningful distinctions that influence product strategy, go-to-market planning, and care delivery integration. When analyzed by drug class, the landscape includes Amylin Analogs with Pramlintide; GLP-1 Agonists such as Dulaglutide, Exenatide, Liraglutide, and Semaglutide; Lipase Inhibitors exemplified by Orlistat; and Serotonin Receptor Modulators like Locaserin. These classes differ by mechanism of action, safety profiles, and typical patient selection criteria, thereby guiding clinical positioning and evidence generation priorities.
Administration route segmentation differentiates injectables-delivered via auto-injectors, prefilled pens, or vials and syringes-from orals available as capsules and tablets. Route of administration affects adherence patterns, device partnerships, cold-chain logistics, and patient education needs. Distribution channel segmentation between offline and online pathways further shapes access models, with brick-and-mortar pharmacy and clinic networks interacting differently with digital pharmacies, telehealth prescribing, and direct-to-patient fulfillment. End-user segmentation spans ambulatory care centers, home care settings, hospitals, and specialty clinics; within specialty clinics, distinctions among endocrinology clinics, general practice clinics, and weight loss clinics drive differences in follow-up intensity, diagnostic workup, and ancillary service requirements.
Understanding these intersecting segmentation vectors enables more precise targeting of clinical trials, payer dossiers, and commercial tactics. By aligning product attributes with the operational realities of specific administration routes, distribution channels, and care settings, stakeholders can refine positioning, prioritize evidence generation, and design support services that materially improve uptake and adherence.
Differentiated regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that dictate tailored regulatory, reimbursement, and operational strategies
Regional dynamics create divergent regulatory, reimbursement, and operational conditions that shape how anti-obesity therapeutics are adopted and scaled. In the Americas, regulatory pathways and payer debates around long-term treatment models are driving intensive stakeholder engagement and localized evidence generation to support coverage and access decisions. Clinical practice patterns and consumer expectations in this region also accelerate demand for both specialty clinic adoption and home-based care models.
In Europe, Middle East & Africa, diverse regulatory regimes and heterogeneous reimbursement systems require tailored regulatory strategies and differentiated pricing approaches. Stakeholders must navigate variable clinical guideline uptake and sometimes fragmented distribution networks. Conversely, Asia-Pacific presents rapid adoption of novel therapeutics in some markets, supported by robust manufacturing capabilities and growing digital health ecosystems, while other markets in the region demand culturally sensitive engagement and local evidence to support clinician acceptance. Across all regions, cross-border supply chain considerations, tariff implications, and device compatibility issues underscore the importance of region-specific operational planning.
Taken together, regional insight demands a portfolio approach to regulatory submissions, payer engagement, and commercial deployment, with a focus on local evidence generation, logistics optimization, and adaptive pricing strategies to reflect payer expectations, clinical pathways, and distribution infrastructures.
Company-level strategic imperatives emphasizing collaboration, device integration, real-world evidence, and supply resilience to secure competitive advantage in anti-obesity therapeutics
Competitive dynamics are defined by a mix of established pharmaceutical firms, emerging biotech innovators, and device partners focused on delivery systems. Across therapeutic classes, companies are investing in combination strategies, formulation improvements, and device ergonomics to differentiate offerings and improve patient adherence. Collaboration between biologics developers and device manufacturers is increasingly common, reflecting the need to pair pharmacology with user-friendly administration solutions.
Corporate strategies also reflect a balance between expanding clinical indications and protecting supply continuity. Licensing deals, co-development agreements, and manufacturing partnerships are being used to accelerate access to key components and scale commercial capacity. Regulatory interactions and real-world evidence programs play a central role in shaping competitive advantage, as outcomes data influence payer negotiations and clinician confidence. Additionally, active intellectual property management and lifecycle planning remain critical to preserving therapeutic positioning while pursuing incremental innovations such as new formulations or delivery platforms.
Taken together, company-level insights emphasize execution across clinical development, device integration, supply chain resilience, and payer engagement. Organizations that synchronize these elements with targeted commercialization playbooks and robust evidence generation will gain a sustained edge in an increasingly crowded therapeutic arena.
Actionable recommendations for leaders to align evidence generation, device strategy, supply resilience, payer engagement, and agile commercialization to accelerate adoption
Industry leaders should prioritize an integrated strategy that aligns clinical development, device design, supply chain resilience, and payer engagement. First, invest in targeted evidence generation that demonstrates long-term clinical outcomes, safety across diverse populations, and real-world effectiveness in the settings where the product will be used, including ambulatory, hospital, and home care environments. Second, build robust device and adherence support programs that address route-specific challenges for injectables and oral administration, and pair these with digital health solutions to enable monitoring and patient support.
Third, proactively fortify supply chains by diversifying suppliers, exploring nearshore manufacturing options, and conducting scenario planning for tariff and trade disruptions to maintain continuity of supply. Fourth, engage payers and policy makers early with transparent value models, outcomes-based contracting options, and compelling economic data tailored to regional reimbursement frameworks. Finally, adopt an agile commercialization approach that customizes distribution strategies for offline and online channels and adapts training and support for specialty clinics, endocrinology practices, generalist providers, and weight loss clinics.
Implementing these recommendations requires cross-functional coordination, clear governance, and measurable KPIs to track adoption, adherence, and value realization. Organizations that act on these priorities will be better positioned to accelerate uptake, protect margins, and deliver improved patient outcomes.
Robust hybrid research approach integrating primary interviews, secondary verification, data triangulation, and expert validation to ensure reliable and practical insights
The research methodology underpinning this analysis combines structured primary research with rigorous secondary interrogation and iterative expert validation. Primary research included in-depth interviews with clinical specialists, supply chain managers, regulatory advisors, and commercial leaders to surface practical constraints, adoption drivers, and payer engagement priorities. These interviews informed hypothesis generation and guided targeted follow-ups to validate operational assumptions across therapeutic classes and care settings.
Secondary research drew on peer-reviewed clinical literature, regulatory filings, public policy documents, and device registries to corroborate clinical evidence, safety signals, and approval timelines. Data triangulation techniques integrated qualitative insights with quantitative indicators from clinical trial registries, procurement patterns, and public procurement notices to build a robust evidence base. Finally, findings were stress-tested through expert panels composed of clinicians, payers, and industry executives to confirm plausibility, refine interpretations, and identify practical implications for commercialization and supply chain strategy.
Transparency, reproducibility, and iterative expert feedback were central to the approach, enabling the analysis to capture both near-term operational realities and longer-term strategic implications for therapeutic classes, administration routes, distribution channels, and end-user settings.
Conclusion synthesizing therapeutic, delivery, regional, and operational imperatives that will determine durable clinical and commercial success in obesity therapeutics
The conclusion synthesizes the report’s principal insights: therapeutic innovation, delivery and device evolution, regional and tariff-driven operational shifts, and nuanced segmentation dynamics collectively define the modern anti-obesity prescription drug landscape. As GLP-1 Agonists and Amylin Analogs gain prominence, stakeholders must adapt clinical pathways, invest in adherence-focused device solutions, and tailor payer narratives to demonstrate sustained value in diverse care settings.
Operational resilience will differentiate successful programs, particularly in the face of tariff-induced supply chain pressures that prompt manufacturers and distributors to rethink sourcing and manufacturing footprints. Regional strategies must balance centralized evidence generation with localized implementation tactics responsive to regulatory, reimbursement, and cultural differences. Ultimately, companies that integrate clinical evidence, device usability, distribution agility across offline and online channels, and proactive payer engagement across ambulatory, hospital, home care, and specialty clinic settings will be best positioned to translate therapeutic advances into improved patient outcomes.
In closing, the intersection of science, delivery innovation, and pragmatic commercialization will determine which interventions achieve durable clinical and commercial success in the evolving landscape of obesity therapeutics.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
182 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Rapid adoption of GLP-1 receptor agonists driven by obesity comorbidity outcomes
- 5.2. Real-world cardiovascular event reduction data boosting anti-obesity drug uptake
- 5.3. Formulation improvements enabling oral administration of injectable obesity therapies
- 5.4. Patient adherence challenges prompting digital health integration for weight management
- 5.5. Payers expanding coverage policies in response to long-term health cost savings evidence
- 5.6. Emerging competitive pipeline drugs targeting dual GIP and GLP-1 therapeutic pathways
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Anti-obesity Prescription Drugs Market, by Drug Class
- 8.1. Amylin Analogs
- 8.1.1. Pramlintide
- 8.2. GLP-1 Agonists
- 8.2.1. Dulaglutide
- 8.2.2. Exenatide
- 8.2.3. Liraglutide
- 8.2.4. Semaglutide
- 8.3. Lipase Inhibitors
- 8.3.1. Orlistat
- 8.4. Serotonin Receptor Modulators
- 8.4.1. Locaserin
- 9. Anti-obesity Prescription Drugs Market, by Administration Route
- 9.1. Injectables
- 9.1.1. Auto-Injectors
- 9.1.2. Prefilled Pens
- 9.1.3. Vials And Syringes
- 9.2. Orals
- 9.2.1. Capsules
- 9.2.2. Tablets
- 10. Anti-obesity Prescription Drugs Market, by End User
- 10.1. Ambulatory Care Centers
- 10.2. Home Care Settings
- 10.3. Hospitals
- 10.4. Specialty Clinics
- 10.4.1. Endocrinology Clinics
- 10.4.2. General Practice Clinics
- 10.4.3. Weight Loss Clinics
- 11. Anti-obesity Prescription Drugs Market, by Distribution Channel
- 11.1. Offline
- 11.2. Online
- 12. Anti-obesity Prescription Drugs Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Anti-obesity Prescription Drugs Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Anti-obesity Prescription Drugs Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Novo Nordisk A/S
- 15.3.2. Eli Lilly and Company
- 15.3.3. GlaxoSmithKline PLC
- 15.3.4. Pfizer Inc.
- 15.3.5. F. Hoffmann‑La Roche Ltd.
- 15.3.6. Boehringer Ingelheim International GmbH
- 15.3.7. Amgen Inc.
- 15.3.8. AstraZeneca PLC
- 15.3.9. Merck & Co., Inc.
- 15.3.10. Takeda Pharmaceutical Company Limited
- 15.3.11. Zydus Lifesciences Limited
- 15.3.12. Teva Pharmaceuticals Company Limited
- 15.3.13. Rhythm Pharmaceuticals, Inc.
- 15.3.14. Currax Pharmaceuticals LLC
- 15.3.15. Gelesis Holdings, Inc.
- 15.3.16. Hanmi Pharm.Co., Ltd.
- 15.3.17. Reddy’s Laboratories Limited
- 15.3.18. Orexigen Therapeutics, Inc.
- 15.3.19. Alizyme Limited
- 15.3.20. Vivus LLC
- 15.3.21. Verdiva Pharma Inc.
- 15.3.22. HK inno.N Corporation
- 15.3.23. BioCon Limited
- 15.3.24. Innovent Biologics, Inc.
- 15.3.25. CHEPLAPHARM Arzneimittel GmbH
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
